VANCOUVER, British Columbia–(BUSINESS WIRE)–（ビジネスワイヤ） — インコグニート・ソフトウェア・システムズは、サービス・オーケストレーション、デバイス管理、ネットワーク・インテリジェンスの各ソリューションを提供する世界有数のプロバイダーで、NEXAを発表しました。NEXAは、ブロードバンド・サービス・プロバイダーが運用データを具体的な対応につなげられるようにするAI駆動型のネットワーク・インテリジェンスおよび自動化プラットフォームです。同プラットフォームは、ネットワーク、デバイス、サービス、加入者のデータを単一のインテリジェンス・レイヤーに統合し、リアルタイムかつ予測的なインサイトを提供します。これにより、サービス・プロバイダーは問題をより早期に特定し、加入者体験をより深く理解し、運用全体でより迅速かつ的確に対応できるようになります。 サービス・プロバイダーが接続サービス以外の面でも差別化を図る中、加入者体験は重要な競争優位の源泉となっています。一方、ネットワークは、アクセス網、エッジ、顧客構内、アプリ、サードパーティー・システムに
Month: September 2026
VANCOUVER, British Columbia–(BUSINESS WIRE)–Incognito Software Systems, ein weltweit führender Anbieter von Lösungen für Service-Orchestrierung, Gerätemanagement und Netzwerkintelligenz, hat heute NEXA vorgestellt, eine KI-gestützte Plattform für Netzwerkintelligenz und Automatisierung, die es Breitbandanbietern ermöglicht, Betriebsdaten in konkrete Maßnahmen umzusetzen. NEXA bündelt Netzwerk-, Geräte-, Dienst- und Kundendaten in einer einzigen Analyseebene und liefert Echtzeit- und prognoseg
VANCOUVER, British Columbia–(BUSINESS WIRE)–Incognito Software Systems, ein weltweit führender Anbieter von Lösungen für Service-Orchestrierung, Gerätemanagement und Netzwerkintelligenz, hat heute NEXA vorgestellt, eine KI-gestützte Plattform für Netzwerkintelligenz und Automatisierung, die es Breitbandanbietern ermöglicht, Betriebsdaten in konkrete Maßnahmen umzusetzen. NEXA bündelt Netzwerk-, Geräte-, Dienst- und Kundendaten in einer einzigen Analyseebene und liefert Echtzeit- und prognoseg
加拿大不列颠哥伦比亚省温哥华–(BUSINESS WIRE)–(美国商业资讯)– 全球领先的服务编排、设备管理及网络智能解决方案提供商 Incognito Software Systems 今日推出 NEXA 。NEXA 是一款由 AI 驱动的网络智能与自动化平台，使宽带服务提供商能够将运营数据转化为实际行动。NEXA 通过统一的智能层整合网络、设备、服务及订户数据，提供实时和预测性洞察，帮助服务提供商更早发现问题，更深入地了解订户体验，并在运营的各个环节更迅速、更明智地采取行动。 随着服务提供商力求在连接服务之外实现差异化竞争，订户体验已成为一项关键竞争优势。然而，网络已发展为复杂的服务平台，覆盖接入网、边缘、用户驻地、应用程序和第三方系统，因而难以迅速发现并解决问题。 NEXA 通过融合跨平台可观测性、AI 赋能的分析能力与自动化功能，应对这一挑战。NEXA 基于开放、可扩展的架构构建，可对来自 Incognito 各项产品及其他数据源的数据进行标准化处理和关联分析。它运用先进分析技术和机器学习，对数据进行整理、识别模式，并关联网络和系统之间的各类信号。由此，服务提供商能够全
加拿大不列颠哥伦比亚省温哥华–(BUSINESS WIRE)–(美国商业资讯)– 全球领先的服务编排、设备管理及网络智能解决方案提供商 Incognito Software Systems 今日推出 NEXA 。NEXA 是一款由 AI 驱动的网络智能与自动化平台，使宽带服务提供商能够将运营数据转化为实际行动。NEXA 通过统一的智能层整合网络、设备、服务及订户数据，提供实时和预测性洞察，帮助服务提供商更早发现问题，更深入地了解订户体验，并在运营的各个环节更迅速、更明智地采取行动。 随着服务提供商力求在连接服务之外实现差异化竞争，订户体验已成为一项关键竞争优势。然而，网络已发展为复杂的服务平台，覆盖接入网、边缘、用户驻地、应用程序和第三方系统，因而难以迅速发现并解决问题。 NEXA 通过融合跨平台可观测性、AI 赋能的分析能力与自动化功能，应对这一挑战。NEXA 基于开放、可扩展的架构构建，可对来自 Incognito 各项产品及其他数据源的数据进行标准化处理和关联分析。它运用先进分析技术和机器学习，对数据进行整理、识别模式，并关联网络和系统之间的各类信号。由此，服务提供商能够全
Technip Energies awarded contrats by Petkim
Technip Energies (PARIS:TE) has been awarded contracts by Petkim, a subsidiary of SOCAR, in connection with the development of a proposed integrated petrochemical complex in Aliağa, Türkiye.
The contracts include the license for a world-scale mixed-feed ethylene cracking unit, as well as the integrated Process Design Package (PDP) and Front-End Engineering Design (FEED) services for the overall complex.
The FEED scope covers the steam cracker designed with an ethylene production capacity of approximately 1,200 KTA1 and a propylene production capacity of 550 KTA, together with an 850 KTA HDPE/LLDPE complex (two 425 KTA trains) and a 550 KTA polypropylene plant integrated with the new cracker.
The awarded scope covers the licensing, PDP and FEED phases of the proposed project and constitutes an important step in its technical development prior to any Final Investment Decision (FID) by PETKIM.
The planned integrated petrochemical complex is intended to produce key petrochemical building blocks used to manufacture a wide range of everyday products, including packaging materials, consumer goods, automotive components and industrial applications.
Stéphane Mespoulhes, Senior Vice President Ethylene and Polyolefins at Technip Energies, commented: “We are pleased to support Petkim at this important stage in the development of its integrated petrochemical complex. By combining our ethylene technology with our engineering capabilities, we will support Petkim through the PDP and FEED phases as the project progresses through its technical development. This early engagement will help establish the technical foundations for an efficient, flexible and competitive project.”
This award was recorded in Q3 2026 in the Project Delivery and Technology, Products & Services segments.
1. Kilotons per annum
About Technip Energies
Technip Energies is a global technology and engineering powerhouse. With leadership positions in LNG, hydrogen, ethylene, sustainable chemistry, and CO2 management, we are contributing to the development of critical markets such as energy, energy derivatives, decarbonization, and circularity. Our complementary business segments, Technology, Products and Services (TPS) and Project Delivery, turn innovation into scalable and industrial reality.
Through collaboration and excellence in execution, our 18,000+ employees across 35 countries are fully committed to bridging prosperity with sustainability for a world designed to last.
Technip Energies generated revenues of €7.2 billion in 2025 and is listed on Euronext Paris. The Company also has American Depositary Receipts trading over the counter.
For further information: www.ten.com
Contacts
Investor Relations
Phillip Lindsay
Vice-President Investor Relations
Tel: +44 207 585 5051
Email: Phillip Lindsay
Media Relations
Jason Hyonne
Head of Press Relations & Social Media
Tel: +33 1 47 78 22 89
Email: Jason Hyonne
Attachments
- Technip Energies awarded engineering and technology contracts by Petkim
- Technip Energies awarded contrats by Petkim
Technip Energies awarded contrats by Petkim
Technip Energies (PARIS:TE) has been awarded contracts by Petkim, a subsidiary of SOCAR, in connection with the development of a proposed integrated petrochemical complex in Aliağa, Türkiye.
The contracts include the license for a world-scale mixed-feed ethylene cracking unit, as well as the integrated Process Design Package (PDP) and Front-End Engineering Design (FEED) services for the overall complex.
The FEED scope covers the steam cracker designed with an ethylene production capacity of approximately 1,200 KTA1 and a propylene production capacity of 550 KTA, together with an 850 KTA HDPE/LLDPE complex (two 425 KTA trains) and a 550 KTA polypropylene plant integrated with the new cracker.
The awarded scope covers the licensing, PDP and FEED phases of the proposed project and constitutes an important step in its technical development prior to any Final Investment Decision (FID) by PETKIM.
The planned integrated petrochemical complex is intended to produce key petrochemical building blocks used to manufacture a wide range of everyday products, including packaging materials, consumer goods, automotive components and industrial applications.
Stéphane Mespoulhes, Senior Vice President Ethylene and Polyolefins at Technip Energies, commented: “We are pleased to support Petkim at this important stage in the development of its integrated petrochemical complex. By combining our ethylene technology with our engineering capabilities, we will support Petkim through the PDP and FEED phases as the project progresses through its technical development. This early engagement will help establish the technical foundations for an efficient, flexible and competitive project.”
This award was recorded in Q3 2026 in the Project Delivery and Technology, Products & Services segments.
1. Kilotons per annum
About Technip Energies
Technip Energies is a global technology and engineering powerhouse. With leadership positions in LNG, hydrogen, ethylene, sustainable chemistry, and CO2 management, we are contributing to the development of critical markets such as energy, energy derivatives, decarbonization, and circularity. Our complementary business segments, Technology, Products and Services (TPS) and Project Delivery, turn innovation into scalable and industrial reality.
Through collaboration and excellence in execution, our 18,000+ employees across 35 countries are fully committed to bridging prosperity with sustainability for a world designed to last.
Technip Energies generated revenues of €7.2 billion in 2025 and is listed on Euronext Paris. The Company also has American Depositary Receipts trading over the counter.
For further information: www.ten.com
Contacts
Investor Relations
Phillip Lindsay
Vice-President Investor Relations
Tel: +44 207 585 5051
Email: Phillip Lindsay
Media Relations
Jason Hyonne
Head of Press Relations & Social Media
Tel: +33 1 47 78 22 89
Email: Jason Hyonne
Attachments
- Technip Energies awarded engineering and technology contracts by Petkim
- Technip Energies awarded contrats by Petkim
Leiden, the Netherlands, September 29, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. Chouraqui will step down as Chief Executive Officer and Executive Director, with immediate effect.
To ensure continuity of leadership, the Board of Directors has appointed Mrs. Leverne Marsh, Chief Commercial Officer, and Mr. Kenneth Lynard, Chief Financial Officer, as Interim Co-CEOs, effective immediately. Mrs. Marsh will lead the patient-focused operations while Mr. Lynard will lead the global corporate functions. The Board has started a formal search for a permanent successor.
Following discussions about the execution of Pharming’s strategic priorities for the next phase of the company, the Board of Directors and Mr. Chouraqui have concluded that their views on how to advance the company’s strategy are not sufficiently aligned. In good consultation, the parties have therefore agreed on a leadership transition.
Pharming’s strategy, pipeline and commitment to patients remain unchanged. Focus remains on executing the strategic priorities and advancing the next phase of growth.
“On behalf of the Board, I would like to express our appreciation for Mr. Chouraqui’s contributions. We wish him well on his next endeavors,” said Richard Peters, Chairman of the Board of Directors of Pharming. “Our immediate priority is to ensure continuity across leadership, while maintaining focus on the continued execution of Pharming’s strategy and its commitment to patients.”
Fabrice Chouraqui added: “It has been a privilege to lead Pharming and to work alongside colleagues who are deeply committed to improving the lives of people with rare diseases. I have continually been inspired by the unwavering patient focus of our teams around the world and am deeply grateful for the passion and dedication they bring to our shared purpose every day. I leave with great confidence in their ability to continue expanding Pharming’s impact for patients and their families.”
To support an orderly transition process, Pharming and Mr. Chouraqui will not comment further beyond this announcement.
About Pharming
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biotechnology company that develops and commercializes innovative medicines for people living with rare immune and genetic diseases.
We combine specialized scientific, medical, regulatory and commercial expertise to advance a focused portfolio of approved medicines and development programs that address significant unmet medical needs. Guided by insights from patients and the wider rare disease community, we are dedicated to delivering innovative therapies for some of the most challenging rare diseases.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming
Saskia Mehring, Head of Corporate Communications
T: +31 6 28 32 60 41
E: media.relations@pharming.com
Forward-looking Statements
This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming’s preclinical studies and clinical trials of its product candidates, Pharming’s clinical and commercial prospects, and Pharming’s expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming’s clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming’s 2025 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming’s actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.
Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
Attachment
Leiden, the Netherlands, September 29, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. Chouraqui will step down as Chief Executive Officer and Executive Director, with immediate effect.
To ensure continuity of leadership, the Board of Directors has appointed Mrs. Leverne Marsh, Chief Commercial Officer, and Mr. Kenneth Lynard, Chief Financial Officer, as Interim Co-CEOs, effective immediately. Mrs. Marsh will lead the patient-focused operations while Mr. Lynard will lead the global corporate functions. The Board has started a formal search for a permanent successor.
Following discussions about the execution of Pharming’s strategic priorities for the next phase of the company, the Board of Directors and Mr. Chouraqui have concluded that their views on how to advance the company’s strategy are not sufficiently aligned. In good consultation, the parties have therefore agreed on a leadership transition.
Pharming’s strategy, pipeline and commitment to patients remain unchanged. Focus remains on executing the strategic priorities and advancing the next phase of growth.
“On behalf of the Board, I would like to express our appreciation for Mr. Chouraqui’s contributions. We wish him well on his next endeavors,” said Richard Peters, Chairman of the Board of Directors of Pharming. “Our immediate priority is to ensure continuity across leadership, while maintaining focus on the continued execution of Pharming’s strategy and its commitment to patients.”
Fabrice Chouraqui added: “It has been a privilege to lead Pharming and to work alongside colleagues who are deeply committed to improving the lives of people with rare diseases. I have continually been inspired by the unwavering patient focus of our teams around the world and am deeply grateful for the passion and dedication they bring to our shared purpose every day. I leave with great confidence in their ability to continue expanding Pharming’s impact for patients and their families.”
To support an orderly transition process, Pharming and Mr. Chouraqui will not comment further beyond this announcement.
About Pharming
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biotechnology company that develops and commercializes innovative medicines for people living with rare immune and genetic diseases.
We combine specialized scientific, medical, regulatory and commercial expertise to advance a focused portfolio of approved medicines and development programs that address significant unmet medical needs. Guided by insights from patients and the wider rare disease community, we are dedicated to delivering innovative therapies for some of the most challenging rare diseases.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming
Saskia Mehring, Head of Corporate Communications
T: +31 6 28 32 60 41
E: media.relations@pharming.com
Forward-looking Statements
This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming’s preclinical studies and clinical trials of its product candidates, Pharming’s clinical and commercial prospects, and Pharming’s expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming’s clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming’s 2025 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming’s actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.
Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
Attachment
2027-2029 Strategy:
Arcadis’ Reset: Focused Growth, Sustainable Value
- Arcadis’ Reset: Focused Growth, Sustainable Value strategy is based on three value creation principles: Focus on Strengths, Simplify around Clients and Drive Performance Culture; all enabled by AI and digital innovation.
- Divestment of the majority of the architecture business and China operations to accelerate value creation, expected to increase the operating EBITDA margin by ~100 basis points1).
- Reduction of ~1,000 FTEs as part of overhead rightsizing targeted in 2027, with continued hiring in growth areas.
- 2027–2029 financial targets:
- Mid-single-digit organic net revenue growth;
- Mid- to high-teens operating EBITDA margin;
- Dividend payout ratio of 30–40% of net income from operations;
- Net debt / operating EBITDA of 1.5–2.5x.
- 2026 Financial guidance reaffirmed: low-single-digit organic net revenue growth, operating EBITA margin of 11.7–12.0%, equivalent to an operating EBITDA margin of 14.3–14.6%.
- Non-financial targets set for 2027-2029 include: client satisfaction, Employee Net Promotor Score, safety improvement, and quantified material impact on sustainability through the Future IMPACT+ framework by 2035.
Amsterdam, 29 September 2026: Arcadis (EURONEXT: ARCAD), the leading global provider of data-driven sustainable design, engineering and consultancy solutions for natural and built assets, is hosting its Capital Markets Day in Amsterdam today to present its 2027–2029 strategy.
Heather Polinsky, Chief Executive Officer, said: “Arcadis’ Reset: Focused Growth, Sustainable Value sharpens our focus on the markets where demand is strongest, and our competitive differentiation is clear. Our people and our culture are what makes this possible, and our work addressing the world’s most complex infrastructure and environmental challenges is what makes it matter. We will invest in our Core and Accelerate industries, apply rigorous performance discipline to Optimize businesses, simplify the organization around clients and strengthen accountability. Combined with our leading market positions, specialist expertise and trusted client relationships, these actions are designed to translate our strategic strengths into stronger growth, higher margins and cash generation. We are building a more focused, higher-performing Arcadis that delivers sustainable value for shareholders, our people and our clients.”
Simon Crowe, Chief Financial Officer, said: “The financial rationale is compelling: a more focused portfolio, a structurally lower cost base and disciplined capital allocation will support higher margins, stronger cash generation and sustainable shareholder returns. The announced divestments are expected to increase the operating EBITDA margin by ~100 basis points1). Beyond this, we will improve win rates, drive billability and apply more targeted sales incentives and differentiated pricing. With most of our key clients currently taking only one of our six services, the cross-selling opportunity is significant.
We will also pursue disciplined bolt-on M&A in our Core and Accelerate industries to build out leading positions and scale in high-growth markets. Together, these actions give us a clear and structured path to a mid-to-high teens operating EBITDA margin by 2029 and we will assess share buybacks from excess cash following each full-year result. With our capital-light model and strong cash-generation potential, we see a clear pathway to more than double EBITDA over time.”
ARCADIS’ RESET: FOCUSED GROWTH, SUSTAINABLE VALUE
The strategy is built on three value-creation priorities: focus on strengths, simplify around clients and drive a performance culture, underpinned by AI and digital innovation.
FOCUS ON STRENGTHS
Arcadis is actively changing its portfolio, concentrating investment in the sectors and growth markets where its expertise is most recognized by clients and where structural demand is strongest.
- Core
- Where Arcadis holds strong leading positions in structurally growing markets
- Includes industries Transportation and Energy & Water, 53% of net revenues1)
- Organic net revenue growth profile of mid to high single digit for Transportation, high single digit for Energy & Water
- Accelerate
- Where Arcadis is scaling rapidly in high-growth sectors, including data centers, life sciences, and semiconductors
- Includes industries Industrial Manufacturing & Technology, 21% of net revenues
- Organic net revenue growth profile of mid to high single digit
- Optimize
- Where Arcadis is applying strict margin discipline and divesting non-core assets, including the majority of the Architecture business and China operations
- Includes Real Estate & Development industry, 26% of net revenues
Arcadis expects the share of Core and Accelerate industries to grow from 74%1) to 85% of Total Net Revenues by 2029, improving the overall quality and profitability of the business.
Environmental services, a leading business representing approximately 20% of net revenues built over 138 years of industry leadership, will be scaled by embedding across all four industries.
SIMPLIFY AROUND CLIENTS
Arcadis is replacing its Global Business Area structure with a model in which profit and loss accountability follows the client, not the person. Account teams will bring together sales and delivery under one accountable team per account, eliminating duplication, speeding up decision-making and enabling more consistent, end-to-end service. A single global services and delivery business, with real-time visibility of talent and skills across the organisation, replaces the current more fragmented model. Continued growth of Arcadis’ Global Excellence Centers will improve consistency, speed and cost efficiency. AI, automation and standardisation will release capacity for higher-value work.
DRIVE PERFORMANCE CULTURE
Arcadis’ people-first culture is embedded in its ownership model. Building on this principle, Arcadis is building a high-performance culture that is clearer and more focused on impact, through performance-linked incentives, clear ownership of client satisfaction, growth and margins. More than 200 leaders were already appointed in 2026 to create a simpler, flatter and more agile business. The Lovinklaan Foundation, Arcadis’ largest shareholder, reinvests dividends in knowledge exchange, innovation and professional development, giving Arcadians a long-term stake in the company’s success. Combined, this will make Arcadis’ performance culture a direct driver of growth, margin and client impact.
EMBED AI AND DIGITAL
Arcadis is embedding AI and digital directly into how it delivers projects, wins work and operates the business. This is already creating value for clients across sectors, improving productivity, quality and outcomes. Arcadis focuses on structured data, partnerships, in-house capability and disciplined scaling to ensure the best ideas reach clients consistently and globally. Its new partnership with Autodesk is one example of how Arcadis embeds AI directly into the workflows, combining technology with Arcadis’ own data, knowledge and engineering expertise. In addition we see strong AI implementation, resulting from working with Nomic, Arcadis’ AI partner purpose-built for engineering. More than 400 engineers across 17 countries now use over 700 engineer-built workflows to analyze drawings, specifications and process complex project information. Both examples highlight AI in action, creating value.
NON-FINANCIAL TARGETS
The strategy is also underpinned by non-financial commitments. Arcadis has set the following non-financial targets for the 2027-2029 cycle:
- Client satisfaction score of 85% or above by 2029;
- Employee Net Promoter Score in the top quartile of the professional services sector;
- 30% improvement in recordable safety incidents and proactive safety behaviours by 2029;
- €100 Billion of client project construction value assessed annually through its Future IMPACT+ sustainability framework by 2035.
1) Based on 2025 full year results
END
ARCADIS INVESTOR RELATIONS
Christine Disch | +31 (0)615376020 | christine.disch@arcadis.com
Investor calendar: https://www.arcadis.com/en/investors/investor-calendar
CAPITAL MARKETS DAY WEBCAST
Today at 14:00 CET: Capital Markets Day 2026 | General | Arcadis
ABOUT ARCADIS
Arcadis is the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets. We are around 34,000 architects, data analysts, designers, engineers, project planners, water management and sustainability experts, all driven by our passion for improving quality of life. As part of our commitment to accelerating a planet positive future, we work with our clients to make sustainable project choices, combining digital and human innovation, and embracing future-focused skills across the environment, energy and water, buildings, transport, and infrastructure sectors. We operate in over 30 countries and reported €5 billion in gross revenues for 2025. www.arcadis.com
REGULATED INFORMATION
This press release contains information that qualifies or may qualify as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
Attachment
